Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24649114 | 0.87 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL26064294 | 0.81 | HPGD (0.44) | SMN1; SMN2ALDH1A1HTTMAPTNPC1 | |
| SCHEMBL25919103 | 0.79 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL288073 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL12804043 | 0.75 | CYP3A4 (0.50) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL30967452 | 0.74 | MCHR1 (0.40) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL30967578 | 0.74 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNAHTTMPL | |
| SCHEMBL288072 | 0.74 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL25809801 | 0.74 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL106132 | 0.74 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1LMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023215801-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023004102-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022266015-A1 | FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS | KUMQUAT BIOSCIENCES INC. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | SMN1; SMN2 1518/4885ALDH1A1 2917/4885LMNA 2568/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | SMN1; SMN2 4580/4885ALDH1A1 1158/4885LMNA 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.